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Background. In March 2004, the OraQuickH rapid HIV antibody test became the first rapid HIV test approved by the US Food
and Drug Administration for use on oral fluid specimens. Test results are available in 20 minutes, and the oral fluid test is non-
invasive. From August 2004–June 2005, we investigated a sudden increase in false-positive results occurring in a performance
study of OraQuickH oral-fluid rapid HIV tests in Minnesota. Methodology/Principal Findings. In a field investigation, we
reviewed performance study data on oral-fluid and whole-blood OraQuickH rapid HIV test device lots and expiration dates and
assessed test performance and interpretation with oral-fluid and whole-blood specimens by operators who reported false-
positive results. We used multivariate logistic regression to evaluate client demographic and risk characteristics associated
with false-positive results. Next, we conducted an incidence study of false-positive OraQuick rapid HIV tests in nine US cities
and tested both oral-fluid and finger-stick whole-blood specimens from clients; reactive tests were confirmed with Western
blot. Sixteen (4.1%) false-positive oral-fluid results occurred in the performance study from April 15, 2004 through August 31,
2004 with unexpired devices from six test lots among 388 HIV-uninfected clients (specificity, 95.9%; 95% CI: 93.4–97.6). Three
test operators who had reported false-positive results performed and interpreted the test according to package-insert
instructions. In multivariate analysis, only older age was significantly associated with false-positive results (adjusted odds
ratio=4.5, 95% CI: 1.2–25.7). In the incidence study, all valid oral-fluid and whole-blood results from 2,268 clients were
concordant and no false-positive results occurred (100% specificity). Conclusions/Significance. The field investigation did
not identify a cause for the increase in false-positive oral-fluid results, and the incidence study detected no false-positive
results. The findings suggest this was an isolated cluster; the test’s overall performance was as specified by the manufacturer.
Citation: Jafa K, Patel P, MacKellar DA, Sullivan PS, Delaney KP, et al (2007) Investigation of False Positive Results with an Oral Fluid Rapid HIV-1/2
Antibody Test. PLoS ONE 2(1): e185. doi:10.1371/journal.pone.0000185
INTRODUCTION
In March 2004, the OraQuickH rapid HIV-1 antibody test
(Orasure Technologies, Bethlehem, Pennsylvania, USA) became
the first rapid Human Immunodeficiency Virus (HIV) test
approved by the US Food and Drug Administration (FDA) for
use on oral fluid specimens. In June 2004, the FDA approved the
test for HIV-2 antibody detection in oral fluid and a name change
to OraQuickH Advance Rapid HIV-1/2 Antibody Test [1].
OraQuick
1 is a qualitative, visually read lateral-flow immunoassay
intended for point-of-care use and is waived for use on oral fluid,
finger-stick, and venipuncture whole blood specimens under CLIA
(the Clinical Laboratory Improvement Amendments of 1988) [2].
The test is performed on an oral fluid specimen, collected by
swabbing the flat pad of the test device once around the outer
surface of the upper and lower gums, or on 5 mL of whole blood
[1]. A reactive test develops reddish-purple lines in both the test
and control zones of the device, while a non-reactive test develops
a reddish-purple line in the control zone of the device and no line
in the test zone [1]. A test is considered invalid if the control or test
line develops outside either the control or test zone, if no control
line develops, or if a red background in the result window makes it
difficult to read the result after 20 minutes [1]. Results are read in
20–40 minutes [1]. Data submitted by the manufacturer as part of
an FDA review for approval indicated a specificity of 99.8% (95%
confidence interval [CI]: 99.6–99.9) on oral fluid and 100% (95%
CI: 99.7–100) on whole blood [1].
As part of its Advancing HIV Prevention initiative, the Centers
for Disease Control and Prevention (CDC) supports rapid HIV
testing methods to increase HIV testing and awareness of HIV
status [3]. In July 2002, the University of Minnesota’s Department
of Family Practice initiated a CDC-sponsored study to evaluate
the performance of OraQuick to test persons with unknown HIV
status in outreach settings [4]. In July 2004, the Minnesota
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increase in false-positive results with the oral-fluid rapid HIV tests.
Test operators described the false-positives as having qualitatively
different test lines, but test-line intensity and color were not
recorded [4]. In this paper we report on: (1) a field investigation to
evaluate false-positive device characteristics, to assess test operator
practices, and to retrospectively evaluate performance study client
characteristics associated with false-positive test results; and (2) an
incidence study of false-positive OraQuick test results to pro-
spectively evaluate client characteristics associated with false-
positive test results and device characteristics including test-line
intensity and color.
METHODS
Field Investigation
Definitions A false-positive rapid HIV test result was defined as
a reactive oral-fluid OraQuick test result followed by a negative
FDA-approved serum or oral-fluid Western blot.
Device investigation We reviewed performance study data
for two time periods: July 1, 2002–April 14, 2004 and April 15,
2004–August 31, 2004. The latter corresponded to the time period
during which 16 false-positive oral-fluid results were reported. To
assess device characteristics associated with false-positive tests, we
reviewed test storage conditions at the performance study site and
examined expiration dates and manufacturer lot numbers of the
tests yielding false-positive results. We requested the manufacturer
to report any manufacturing discrepancies for implicated lots.
Operator investigation We interviewed performance study
operators, all of whom had performed and interpreted tests yield-
ing false-positive results, about any unusual device characteristics
for those tests. To assess operator practices while performing and
interpreting the test we observed operators who reported $1 false-
positive result as they prepared OraQuick devices, performed one
oral-fluid and one finger-stick whole-blood test each on volunteer
specimens, inserted devices into the developer solution, timed the
test, and interpreted results.
Epidemiologic investigation We constructed an epidemic
curve of false-positive results that occurred during the performance
study. To evaluate demographic and risk characteristics potentially
associated with false-positive results, we examined client data
collected at the time of testing during two time periods: July 1,
2002–April 14, 2004 and April 15, 2004–August 31, 2004. In
univariate analyses, we used exact Mantel-Haenszel chi-square
tests and exact 95% confidence limits for odds ratios. We included
variables associated with false-positive results at P#0.25 in
univariate analysis in a multivariate logistic regression model.
We performed all analyses with SAS (version 9.1, SAS Institute,
Cary, North Carolina, USA).
Incidence Study
Rationale From February 1, 2005 through May 31, 2005, we
conducted a multi-site study of the incidence of false positive
results from oral-fluid OraQuick tests because (1) the false-positive
results occurred at the end of the Minnesota performance study
and it was unknown whether similar incidence would continue; (2)
the initial field investigation was retrospective and information on
host factors (e.g., pre-existing medical conditions and interfering
substances) that might be associated with false-positive results
could not be elicited; and, (3) the performance study did not record
test line intensity and color, thereby limiting our ability to
accurately describe false-positive results read within the 20–
40 minute reading window and to determine the degree of under-
ascertainment of faintly reactive devices among operators at other
sites who had not reported any false positives. If a sufficient
number of false-positive results occurred during the incidence
study, we planned a case-control study to assess the associations of
host factors with false-positive results.
Definitions For the purpose of the incidence study, we
defined a negative HIV test result as one in which the client’s
whole-blood rapid HIV test result was non-reactive. We defined
a positive HIV test result as one with a reactive whole-blood rapid
test followed by an FDA-approved positive serum Western blot.
Sample size We based the sample size calculation for the
incidence study on the FDA requirement that, in clinical trials of
rapid HIV tests, the lower bound of the 95% confidence interval
(CI) for specificity must be at least 98% [5]. With a false-positive
incidence of 1.5%, a sample size of 1800 would yield a 95% CI
for specificity of 97.9–99.0 [6]. If we observed a false-positive
incidence $1.5%, the test would not meet FDA specificity
requirements and there would be sufficient false-positives for us
to proceed with the case-control study.
Study settings and methods Three state health departments
conducted the incidence study from February 1, 2005 through
May 31, 2005 at HIV testing sites already using rapid tests in
nine cities: Minneapolis, Minnesota; Madison and Milwaukee,
Wisconsin; and Atlantic City, East Orange, Hackensack, Newark,
New Brunswick and Trenton, New Jersey. Minnesota was invited
to participate because the sudden increase in false-positives was
reported in Minneapolis; other states volunteered to participate.
Clients seeking HIV testing were eligible for enrollment into the
incidence study if they were $18 years old and had no history of
antiretroviral therapy, HIV vaccination, or a previous HIV
diagnosis.
All incidence study participants consented to and received both
whole-blood and oral-fluid OraQuick tests. Participants with
concordant non-reactive rapid test results received a negative
result, while those with concordant reactive rapid test results
received a preliminary positive result. Participants with discordant
rapid test results were informed of both results, offered confirm-
atory testing, and invited to participate in the case-control study.
To assess rapid test specificity, any reactive rapid test result was
followed by a ‘gold standard’ Genetic Systems HIV-1 Western blot
(Bio-Rad Laboratories, Inc., Hercules, California, USA) on serum
specimens. Since sensitivity was not under investigation in the
incidence study, no additional testing was conducted on concor-
dant non-reactive whole-blood and oral-fluid OraQuick tests (such
additional testing was conducted in the performance study and is
reported elsewhere [4]). All study operators had received previous
training on administration and interpretation of OraQuick. To
ensure identification of all false-positive results, we re-trained
operators to interpret and record the intensity and color of all test
lines observed.
Data collection and analysis We used QDS
TM Question-
naire Development System Version 2.3 (Nova Research Com-
pany, Bethesda, Maryland, USA) to record rapid-test results, color
and intensity of test and control lines, invalid results, manufacturer
lot number, and rapid-test operator initials and read times. Sites
also reported Western blot results and routinely collected
demographic and risk characteristics of testing clients enrolled as
study participants. We calculated specificity with a standard
formula and performed all analyses with SAS version 9.1.
Human subjects As a public-health response to an increase
in false-positive test results from an FDA-approved device, CDC
determined the study did not require Institutional Review Board
(IRB) review under human-subjects-protection guidelines. The
Minnesota and Wisconsin IRBs of record concurred. To comply
with human-subjects guidelines in New Jersey, the protocol was
False Positive Rapid HIV Tests
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Services IRB of record.
RESULTS
Field Investigation
Device investigation From July 1, 2002 through April 14, 2004
seven (0.3%) false-positive oral-fluid OraQuick results occurred
with test devices from four different lots among 2017 HIV-
uninfected clients (Fig. 1). From April 15, 2004 through August 31,
2004, 16 (4.1%) false-positive oral-fluid OraQuick results occurred
with test devices from six different lots among 388 HIV-uninfected
clients (specificity, 95.9%; 95% CI: 93.4–97.6) (Fig. 1). All false-
positive tests were stored and used within the manufacturer’s
temperature specifications, and used before their expiration date.
The manufacturer reported that all implicated lots were manu-
factured and shipped according to standard procedures and that
all device components were within manufacturer specifications.
Operator investigation Three of the four operators who had
observed the 16 false-positive test results were interviewed; one
had left the study and could not be contacted. All were involved in
the performance study from start to finish and reported that most
test lines they observed in devices with false-positive oral-fluid
results were faint; some test lines were described as gray. When test
lines were faint operators, who worked in teams conducting
outreach testing, reported that they occasionally sought the
opinion of another operator on whether the test was reactive or
non-reactive. Operators did not report any unusual environmental
conditions during the period when the increased number of false-
positive tests was reported. We observed that all operators used the
rapid test on volunteer oral-fluid and whole-blood specimens in
accordance with the package insert and interpreted results
correctly.
Epidemiologic investigation No client demographic or risk
factors were associated with false positive oral-fluid test results
during July 1, 2002–April 14, 2004. Further host-factor analyses
were restricted to 382 (94%) clients tested in the performance
study during April 15, 2004–August 31, 2004 for whom complete
demographic and risk data were available. In univariate analyses
age, non-Black race, injection drug use, and male-to-male sex were
associated with false-positive results at a threshold of P#0.25
(Table 1). In the multivariate logistic regression model, only older
age was significantly associated (P=0.02) with false-positive oral-
fluid results (Table 1).
Incidence Study
Participant characteristics Of 3067 eligible clients at all study
sites who received a whole-blood rapid test, 2283 (74%) consented
to an oral-fluid rapid test. Of 2283 clients who provided consent,
15 (0.6%) were excluded from analyses because either their test
results were read before 20 minutes (n=9) or their records had
missing data (n=6). Demographic and risk characteristics of the
remaining 2268 clients are summarized in Table 2.
Test results Of the 2268 clients tested, results of one (0.04%)
test using whole blood and six (0.3%) using oral fluid were invalid.
This difference in the number of invalid results by specimen type
was not statistically significant (Fisher’s exact test, P=0.12). Nine
(0.4%) clients had reactive tests on both oral fluid and whole
blood, and 2253 (99.3%) had non-reactive tests on both specimens
(Table 3). Valid oral-fluid and whole-blood test results were 100%
concordant, and all reactive rapid tests were confirmed as positive
by serum Western blot (100% specificity).
Device characteristics No participant had an invalid test on
both whole-blood and oral-fluid specimens. Of the six invalid oral-
fluid results, one had a partial reddish-purple test line, three had
a red background that did not clear at 20 minutes, and two
Figure 1. Epidemic curve of false-positive OraQuick rapid HIV antibody test results, oral fluid, by Month and Lot, University of Minnesota study, July
2002 through August 2004.
doi:10.1371/journal.pone.0000185.g001
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results had non-reactive whole-blood results and non-reactive
repeat oral-fluid results. Two oral fluid tests classified as non-
reactive were described by the same reader as having a faint gray
test line (Table 3); both clients had non-reactive finger-stick results.
The test devices were used on two different days, were read at 20
and 21 minutes respectively, and were from two different lots. The
first client whose oral-fluid test device had a gray line was a 62-
year old White male who reported multiple sex partners and tested
anonymously. The second client was a 47-year old Asian male
who reported sex with a known HIV-infected male partner six
weeks prior to the current HIV test; he had a negative HIV test
result three months prior to the current test. No further HIV test
results are available for either client as they did not return to the
study site for subsequent testing.
DISCUSSION
As part of a two year rapid HIV test performance study, a cluster
of 16 false-positive oral fluid OraQuick tests was reported from
April 15, 2004 through August 31, 2004 during which the
specificity of the test fell below the FDA required minimum of
98% [4,5]. However, in the first 18 months of the performance
study, and in three other contemporaneous studies, oral-fluid
OraQuick tests demonstrated a specificity $99.6% [4]. The
overall specificity of the oral-fluid test for the entire duration of the
performance study was 99.0% (95% CI: 98.6–99.4) and there were
23 oral-fluid false positives, 1 oral-fluid false negative, and 2 whole
blood false positives [4]. Our field investigation did not suggest
a specific cause for the cluster, and our subsequent incidence study
detected no false-positive tests. The lack of any false-positive tests
despite testing 2268 clients at nine sites during the 4-month
incidence study suggests that the observed cluster was isolated and
that, even as false-positive results occur at expected rates (we
expected two to nine false-positives in the incidence study), future
occurrences of false-positive tests may not be evenly distributed
over time. While false-positive oral fluid results reported in the
performance study occurred in outreach sites, such results have
also been reported in a static clinical site (Shelley Facente, personal
communication) [7].
The retrospective nature of the field investigation imposed
certain limitations. First, we did not observe test operators
Table 1. Demographic and risk characteristics of 382 clients who had a true-negative or false-positive oral fluid OraQuick Rapid
HIV-1 Antibody Test result—University of Minnesota performance study, April 15, 2004 through August 31, 2004.
..................................................................................................................................................
Client characteristics Test Result OR (95% CI)
a AOR (95% CI)
True negative False positive
n=366 (%) N=16 (%)
Demographic Characteristics
Age
b
,37 years 173 (47) 3 (19) 1.0 1.0
$37 years 193 (53) 13 (81) 3.9 (1.0–21.5) 4.5 (1.2–25.7)*
Gender
Female 131 (36) 4 (25) 1.0 –
Male 235 (64) 12 (75) 1.7 (0.5–7.2) –
Race
Black 244 (67) 8 (50) 1.0 1.0
White 98 (27) 7 (44) 2.2 (0.7–7.1) 1.6 (0.4–6.4)
A/PI/AI/AN/Other 24 (6) 1 (6) 1.3 (0.03–10.2) 1.4 (0.03–12.2)
Ethnicity
Hispanic 16 (4) 1 (6) 1.0 –
Non-Hispanic 350 (96) 15 (94) 1.5 (0.03–10.7) –
Risk Behaviors
c
IDU 17 (5) 3 (19) 4.7 (0.8–19.6) 4.4 (0.5–28.5)
Sex partner of IDU 25 (7) 3 (19) 3.1 (0.5–12.5) 1.2 (0.2–7.0)
MSM or sex partner of MSM 11 (3) 2 (13) 4.6 (0.5–24.2) 4.1 (0.3–28.2)
Sex partner has HIV/AIDS 7 (2) 1 (6) 3.4 (0.1–29.4) –
STD diagnosis 34 (9) 1 (6) 0.7 (0.02–4.5) –
Sex for money 37 (10) 2 (13) 1.3 (0.1–5.9) –
$4 sex partners 106 (29) 4 (25) 0.8 (0.2–2.8) –
No reported risk 201 (55) 7 (44) 0.6 (0.2–2.0) –
OR, odds ratio; AOR, adjusted odds ratio; CI, confidence interval; A/PI/AI/AN/Other, Asian/Pacific Islander/American Indian/Alaska Native/Other; IDU, injection drug users;
MSM, men who have sex with men; STD, sexually transmitted diseases.
aValues in bold font represent P#0.25; variables included in the logistic regression model (see methods).
bAge was categorized into a dichotomous variable with 37 years as the cutoff as this was the median age of performance study clients during both July 1, 2002–April 14,
2004 and April 15, 2004–August 31, 2004.
cRisk behaviors are not mutually exclusive.
*P,0.05
doi:10.1371/journal.pone.0000185.t001
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PLoS ONE | www.plosone.org 4 January 2007 | Issue 1 | e185Table 2. Demographic characteristics and HIV risk behaviors of 2268 clients whose finger-stick whole blood and oral fluid
specimens were tested with the OraQuick Advance rapid HIV test, by state—incidence study, February 2005 through May 2005.
..................................................................................................................................................
Client characteristics
Minnesota New Jersey Wisconsin All Sites
n=1039 (%) n=304 (%) n=925 (%) n=2268 (%)
Demographic Characteristics
Age in years
,37 years 748 (72) 220 (72) 722 (78) 1690 (75)
$37 years 291 (28) 84 (28) 203 (22) 578 (25)
Gender
Female 295 (28) 155 (51) 324 (35) 774 (34)
Male 743 (72) 149 (49) 601 (65) 1493 (66)
Transgender 1 (0) 0 (0) 0 (0) 1 (0)
Race
Black, Non-Hispanic 259 (25) 203 (67) 639 (69) 1101 (49)
White, Non-Hispanic 626 (60) 47 (15) 206 (22) 879 (39)
A/PI/AI/AN/Other 98 (10) 6 (2) 38 (4) 142 (6)
Unknown 56 (5) 48 (16) 42 (5) 146 (6)
Ethnicity
Hispanic 54 (5) 43 (14) 42 (5) 139 (6)
Non-Hispanic 985 (95) 261 (86) 883 (95) 2129 (94)
Risk Behaviors
a
IDU 18 (2) 11 (4) 10 (1) 39 (2)
Sex partner of IDU 41 (4) 15 (5) 17 (2) 73 (3)
Sex while using non-injection drugs 276 (27) 233 (77) 267 (29) 776 (34)
MSM or sex partner of MSM 304 (29) 16 (5) 47 (5) 367 (16)
Sex partner of person with HIV/AIDS 56 (5) 13 (4) 14 (2) 83 (4)
STD diagnosis 125 (12) 82 (27) 285 (31) 492 (22)
A/PI/AI/AN/Other, Asian/Pacific Islander/American Indian/Alaska Native/Other; IDU, injection drug user; MSM, men who have sex with men; STD, sexually transmitted
diseases.
aRisk behaviors are not mutually exclusive.
doi:10.1371/journal.pone.0000185.t002
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Table 3. OraQuick Advance rapid HIV antibody test results for 2268 clients tested with oral fluid, Incidence Study, February 2005 to
June 2005.
..................................................................................................................................................
Minnesota New Jersey Wisconsin Total
Test Results n=1039 (%) n=304 (%) n=925 (%) n=2268 (%)
Non-reactive 1033 (99.4) 302 (99.3) 918 (99.3) 2253 (99.3)
‘T’ zone description:
No line 1032 302 916 2250
Visible line appearing gray 0 0 2 2
Don’t know if line visible 1 0 0 1
Reactive 4 (0.4) 2 (0.7) 3 (0.3) 9 (0.4)
Test line intensity
a:
Darker than control 1 2 1 4
As dark as control 2 0 2 4
Fainter than control 1 0 0 1
Invalid 2 (0.2) 0 (0) 4 (0.4) 6 (0.3)
aTest line intensity of test device compared to test line intensity of low-positive external control.
doi:10.1371/journal.pone.0000185.t003
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
False Positive Rapid HIV Tests
PLoS ONE | www.plosone.org 5 January 2007 | Issue 1 | e185performing and interpreting the tests at the time they identified the
false-positive results. Although we did not note these practices
when the operators performed the tests under our observation,
over-collection of oral-fluid specimens (swabbing the outer gums
more than once), over-interpretation of the test line, or other
practices such as specimen contamination and erroneous re-
cording of results might have contributed to false-positive results.
The manufacturer intends to systematically evaluate the influence
of oral fluid over-collection on test specificity (Stephen R. Lee,
OraSure Technologies, personal communication). Second, we
were unable to accurately capture the appearance of the false-
positive devices at the time they were identified. We used optical
densitometry and detected a peak in the test zone of false-positive
devices when compared to a non-reactive device but these
readings were obtained days to weeks after the test was run and
the devices may have changed appearance in the interim. We were
therefore unable to make valid comparisons between interpreta-
tions of false-positive devices among operators who had identified
them versus operators who had not. Third, we were unable to
obtain data retrospectively from persons with false-positive results
about medical conditions (e.g., Epstein-Barr virus infection,
hepatitis A and B infection, rheumatoid factor, or multiparity)
which might be associated with false-positive OraQuick Advance
results [1].
Older age was significantly associated with false-positive results
in the performance study, but age may be a marker for unmea-
sured conditions that increase with age and that are associated
with false-positive results (e.g., prevalence of markers of hepatitis B
infection among injection drug users and men who have sex with
men). Since no oral-fluid false positives were detected in the
incidence study, we were unable to compare age differences
between false positives in the performance and incidence study
populations. Despite the lack of statistical significance, false-
positive results in the performance study occurred more often in
specific groups such as injection drug users and men who have sex
with men. These findings suggest one or more unmeasured host
and site-specific factors may have interacted to produce the
cluster. For example, higher rates of viral hepatitis are known to
occur in these groups. Both the incidence study and the
performance study had similar representation from these groups.
As with any diagnostic test, comprehensive instructions for
performing and interpreting the OraQuick test are essential. The
OraQuick Advance package insert does not specify how to
interpret partial test lines or visible test lines that do not have
a discernable reddish-purple color [1]. In the incidence study, two
test lines described by the same operator as very faint or gray were
interpreted as non-reactive, and one incomplete reddish-purple
test line was considered invalid. All three of these test lines
occurred among clients with a negative finger-stick rapid test
result; since OraQuick is more sensitive with finger-stick whole
blood than with oral fluid it is unlikely these were true positives
[1,4]. In the original Minnesota performance study and perhaps
elsewhere [7], these types of test results may have been reported as
reactive. Without guidance from the manufacturer other clusters
of false-positive results might occur, in part because of differential
interpretation. The manufacturer should revise the package insert
to specify how to interpret partial lines and visible lines in the test
zone that do not appear reddish-purple.
With proper training to ensure correct use and interpretation,
the OraQuick Advance oral-fluid rapid HIV test can be used
successfully as a point-of-care test, although the test has a lower
specificity with oral fluid than with whole blood [1,4,7]. Regardless
of the specimen type, clients should be counseled that a reactive
rapid HIV test result is preliminary and must be confirmed [8,9].
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